Aceto strengthens its focus on the pharmaceutical and biopharmaceutical industry with acquisitions and investments in facilities


Aceto is a global manufacturer and supplier of differentiated specialty ingredients: offering over 3,000 chemical compounds for the pharmaceutical, nutraceutical, agricultural and specialty chemical industries. The company announced this week that it has consolidated and integrated six manufacturing acquisitions: boosting its offering in the biopharmaceutical industry.

His spending spree includes the acquisition of A&C; A&C Bio Buffer; Cascade Chemistry and Finar.

“These acquisitions make a significant difference,”​Gilles Cottier, CEO, told BioPharma-Reporter.

“Aceto historically offered a few niche raw materials used in the biopharmaceutical industry, but overall we had a modest presence. Our acquisition of A&C, A&C Bio Buffer and Finar dramatically changed this equation, significantly expanding our footprint in life sciences.

Build a portfolio of components for upstream and downstream processing

Aceto started monitoring the demand for high quality critical GMP excipients and raw materials in the pharmaceutical and biopharmaceutical sectors before COVID.

However, he notes that the pandemic has exposed the fragility of global supply chains, making his strategy more relevant than ever.

Aceto’s manufacturing acquisitions

  • A&C ​- a global GMP manufacturer of specialty excipients, buffers, processing solutions and raw materials for the biopharmaceutical industry.
  • A&C Bio Buffer– a GMP manufacturer of buffer products and custom chemical blends used in the manufacture of pharmaceuticals and biopharmaceutical vaccines.
  • Cascading Chemistry – a manufacturer of APIs, regulatory raw materials and advanced intermediates, enabling Aceto to provide customers with enhanced support throughout the drug development process and better access to expanded North American manufacturing.
  • Finar– a manufacturer, supplier and distributor of pharmaceutical excipients, laboratory chemicals, aquaculture inputs and food grade additives.
  • Islechem – a specialty chemical manufacturing organization that also provides contract research and development, analytical services and technical support services.
  • Syntor Fine Chemicals ​- a fine chemicals manufacturer offering process development and R&D services.

“Aceto historically offered a strong network of suppliers to solve customer supply issues, especially for small molecules,”Cottier said. “The acquisitions also enable us to offer in-house manufacturing solutions for a variety of routine and specialty products, including biologics, and enhance our R&D and development capabilities, with our R&D organizations now totaling more than 50 scientists, two-thirds of whom hold doctorates. ”

“With our acquisition of A&C, we can now offer excipients, buffers, process solutions, critical raw materials and WFI,” Collier explained.

“To meet the high demand for customization in the biopharmaceutical industry, we can now offer GMP services including custom formulation development, GMP manufacturing and GMP sub-packaging in batch-specific packaging.

“Both A&C and Finar offer a rich and highly complementary excipient portfolio that serves both the pharmaceutical and biopharmaceutical industries with a large number of parenteral-grade materials available.

“In addition, we are building a portfolio of components used in upstream and downstream processing, including amino acids, powdered buffers, cell culture media ingredients, and low endotoxin ingredients such as sucrose, among others.

“While Aceto has long prided itself on its regulatory and quality expertise, acquisitions have provided critical mass to move faster.”

$25 million investment in pharmaceutical facilities

Now, the company will invest $25 million in three of the newly acquired facilities.

“Most important is a full-scale cGMP expansion at our premier Cascade facility in Eugene, Oregon,”Cottier said.

“This site is currently developing and scaling small molecule APIs through Phase II, while the new facility will support customers through Phase III, and potentially commercialization. We will also double the R&D capacity of the Oregon facility. We expect these expansions to be completed by the third quarter of 2022.”

Meanwhile, the company has already increased its production capacity and capabilities to its Installation of Islechem in Grand Island, NY.

“We have completely renovated 10,000 square feet of laboratory space to allow for business growth. The Grand Island and Eugene R&D organizations are working closely together to meet the growing needs of pharmaceutical drug development. We expect to increase the workforce by 40% over the next six months to support expected growth.

Additionally, the company has a robust water for injection (WFI) operation at A&C Ireland and has begun construction of its A&C Montreal facility to create redundant WFI capability in North America, which will allow it to deploy its GMP buffer offer in North America. customer base. This capability is expected to be live later in 2022.

Finally, the company remains on the lookout for other acquisition opportunities, added Cottier.

Hybrid manufacturing/distribution model

The acquisition of the six companies allows Aceto to create what it calls a “unique hybrid manufacturing/distribution model”, which it has built by adding manufacturing operations in key strategic global markets: covering North America North, Europe and India.

“We view our hybrid model as one that allows for more flexibility and agility to respond quickly and efficiently to customer needs,”Cottier said.

“We saw this as necessary before COVID, and it’s even more true today. As capacity has been consolidated into fewer and larger organizations, there have been fewer options for drugmakers when demand is high.

“Our assumption was that a different model was needed and could play a significant role in alleviating these constraints, expanding our internal capabilities and integrating them with our well-established network of carefully selected external vendors.

“COVID has amplified and accelerated some of what we saw coming – we are delighted to have been at the forefront of these developments and to be able to offer these enhanced solutions to our customers now and in the future. .”


Comments are closed.